342 related articles for article (PubMed ID: 10819372)
1. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.
Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Chikhlikar PR; Ghosh N; Trivedi TI
Ann Surg Oncol; 2000 May; 7(4):305-11. PubMed ID: 10819372
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of biomarkers in squamous cell carcinoma of the tongue: multivariate analysis.
Vora HH; Shah NG; Patel DD; Trivedi TI; Chikhlikar PR
J Surg Oncol; 2003 Jan; 82(1):34-50. PubMed ID: 12501167
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of CD44: a useful independent predictor of prognosis in patients with colorectal carcinomas.
Bhatavdekar JM; Patel DD; Chikhlikar PR; Trivedi TI; Gosalia NM; Ghosh N; Shah NG; Vora HH; Suthar TP
Ann Surg Oncol; 1998 Sep; 5(6):495-501. PubMed ID: 9754757
[TBL] [Abstract][Full Text] [Related]
5. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
[TBL] [Abstract][Full Text] [Related]
6. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.
Mack L; Kerkvliet N; Doig G; O'Malley FP
Hum Pathol; 1997 Aug; 28(8):974-9. PubMed ID: 9269835
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
[TBL] [Abstract][Full Text] [Related]
8. [Survival of patients with laryngeal cancer and some prognostic factors].
Gryczyński M; Kobos J; Murlewska A; Pietruszewska W
Otolaryngol Pol; 2003; 57(3):329-40. PubMed ID: 14524174
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.
Ozretic P; Alvir I; Sarcevic B; Vujaskovic Z; Rendic-Miocevic Z; Roguljic A; Beketic-Oreskovic L
Int J Biol Markers; 2018 Jan; 33(1):109-115. PubMed ID: 28777433
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of CD44 and c-erb-B2 protein overexpression in patients with gastric cancer.
Doventas A; Bilici A; Demirell F; Ersoy G; Turna H; Doventas Y
Hepatogastroenterology; 2012 Oct; 59(119):2196-201. PubMed ID: 23435135
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers.
Zhang GJ; Kimijima I; Abe R; Watanabe T; Kanno M; Hara K; Tsuchiya A
Anticancer Res; 1998; 18(3B):1989-98. PubMed ID: 9677455
[TBL] [Abstract][Full Text] [Related]
14. Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma.
Bhatavdekar JM; Patel DD; Chikhlikar PR; Shah NG; Vora HH; Ghosh N; Trivedi TI
Dis Colon Rectum; 2001 Apr; 44(4):523-33. PubMed ID: 11330579
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
[TBL] [Abstract][Full Text] [Related]
16. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis.
Pellikainen MJ; Pekola TT; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
J Clin Pathol; 2003 Mar; 56(3):214-20. PubMed ID: 12610102
[TBL] [Abstract][Full Text] [Related]
17. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2.
Vollmer RT; Humphrey PA; Swanson PE; Wick MR; Hudson ML
Cancer; 1998 Feb; 82(4):715-23. PubMed ID: 9477105
[TBL] [Abstract][Full Text] [Related]
18. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Malamou-Mitsi V; Gogas H; Dafni U; Bourli A; Fillipidis T; Sotiropoulou M; Vlachodimitropoulos D; Papadopoulos S; Tzaida O; Kafiri G; Kyriakou V; Markaki S; Papaspyrou I; Karagianni E; Pavlakis K; Toliou T; Scopa C; Papakostas P; Bafaloukos D; Christodoulou C; Fountzilas G
Ann Oncol; 2006 Oct; 17(10):1504-11. PubMed ID: 16968874
[TBL] [Abstract][Full Text] [Related]
20. COX2 overexpression is a prognostic marker for Stage III breast cancer.
Kim HS; Moon HG; Han W; Yom CK; Kim WH; Kim JH; Noh DY
Breast Cancer Res Treat; 2012 Feb; 132(1):51-9. PubMed ID: 21533532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]